## VCYT: Veracyte, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.4% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($38.70)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Veracyte, Inc. $VCYT Shares Sold by Nikko Asset Management Americas Inc.**
- Source: MarketBeat | 20251214T110936 | Somewhat-Bullish | Relevance: 100%
- Nikko Asset Management Americas Inc. decreased its holdings in Veracyte, Inc. (NASDAQ:VCYT) by 27.2% during the second quarter, selling over 614,000 shares. Other institutional investors also adjusted their stakes in the biotechnology company. Veracyte recently reported strong quarterly earnings, beating analyst estimates, and has received a "Moderate Buy" consensus rating from Wall Street analysts.

**2. First Trust Advisors LP Raises Holdings in Veracyte, Inc. $VCYT**
- Source: MarketBeat | 20251211T160936 | Somewhat-Bullish | Relevance: 100%
- First Trust Advisors LP has increased its stake in Veracyte, Inc. (NASDAQ:VCYT) by 2.7%, bringing its total holdings to 1,071,932 shares valued at approximately $28.97 million. This comes despite significant insider selling, with directors disposing of over 134,000 shares worth nearly $5.9 million in the last 90 days. Veracyte recently exceeded quarterly earnings and revenue estimates, leading analysts to maintain a "Moderate Buy" consensus rating with an average price target of $45.43.

**3. JPMorgan Chase & Co. Buys 243,111 Shares of Veracyte, Inc. $VCYT**
- Source: MarketBeat | 20251210T170919 | Somewhat-Bullish | Relevance: 100%
- JPMorgan Chase & Co. significantly increased its stake in Veracyte, Inc. (NASDAQ:VCYT) by 259%, purchasing an additional 243,111 shares, bringing its total ownership to 336,978 shares valued at approximately $9.11 million. This comes as Veracyte reported better-than-expected quarterly earnings with an EPS of $0.51 and revenue up 13.8% year-over-year, alongside a "Moderate Buy" analyst consensus despite insider selling.

**4. Next Century Growth Investors LLC Lowers Stock Holdings in Veracyte, Inc. $VCYT**
- Source: MarketBeat | 20251210T160925 | Neutral | Relevance: 99%
- Next Century Growth Investors LLC significantly reduced its stake in Veracyte, Inc. (NASDAQ:VCYT) by 49.0% in the second quarter, selling 233,442 shares and retaining 242,774 shares valued at $6.56 million. This reduction comes alongside recent insider selling by the CEO and SVP. Despite this, Veracyte reported strong Q3 earnings, surpassing analyst estimates with EPS of $0.51 and revenue of $131.9 million, and holds a "Moderate Buy" consensus analyst rating with a target price of $45.43.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $48 | $40 | +20% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.05M) |
| Sells | 24 ($4.46M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 70.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 16.5% (+68.9%)
- Vanguard Group Inc: 10.8% (+5.0%)
- Artisan Partners Lim: 9.3% (+16.6%)
- FMR, LLC: 8.6% (-16.2%)
- ARK Investment Manag: 5.7% (+17.5%)

### Key Risks

1. High beta (1.83) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Insider selling cluster: $4.5M in recent transactions.
3. Elevated short interest (8.1%): bears positioning against stock.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.78 indicates undervaluation relative to growth. Balance sheet: strong liquidity (6.2x), low leverage (D/E 0.09). Analyst sentiment positive (1 raises, avg +20%). Insider selling cluster ($4.5M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.4B |
| Beta | 1.83 |
| 52W Range | $22.61 - $50.71 |
| Short Interest | 8.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.78 |
| Forward P/E | 26.7 |
| Current P/E | 26.0 |
| YoY Growth | -2.5% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -6.1% to -3.4% (+2.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 6.4pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.2%) - potential reversal signal. Underperforming sector by 3.1pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.34x) but short-term weakness (below SMA20). MACD histogram bearish (-0.72), momentum weakening. RSI neutral at 50. OFD pattern: +SBL (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.41% (CS: 6) | Weak |
| RSI_14 | 49.7 | Neutral |
| MACD Histogram | -0.72 | Bearish |
| vs SMA20 | 0.971x | Below |
| vs SMA50 | 1.073x | Above |
| vs SMA200 | 1.339x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $42.84
- **Stop Loss:** $38.70 (9.7% risk)
- **Target:** $46.98 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 241
- **Position Value:** $10,324.44
- **Portfolio %:** 10.32%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-24 (Est: $0.39)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.32 | $0.51 | +59.5% |
| 2025Q2 | $0.30 | $0.44 | +48.5% |
| 2025Q1 | $0.20 | $0.31 | +51.3% |
| 2024Q4 | $0.26 | $0.36 | +40.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*